Shots:

• Capsigen to receive $15M up front and is eligible to receive up to ~$42M as research milestones and ~$1.25B as additional payments upon the achievement of development and sales milestones along with royalties on net sales of products resulting from the collaboration
• Biogen to get an exclusive license under Capsigen’s technology for CNS and neuromuscular disease targets
• The collaboration leverages Capsigen’s TRADE platform and associated technologies to identify novel AAV capsids with Biogen’s discovery- development- manufacturing and commercialization capabilities to facilitate the delivery of gene therapies for needy patients

  Ref: GLOBE NEWSWIRE | Image: Biogen